# HR20013 for Nausea and Vomiting Associated With Moderate Emetic Risk Anticancer Agents

> **NCT06554184** · PHASE3 · COMPLETED · sponsor: **Fujian Shengdi Pharmaceutical Co., Ltd.** · enrollment: 706 (actual)

## Conditions studied

- Nausea and Vomiting Associated With Moderate Emetic Risk Anticancer Agents

## Interventions

- **DRUG:** HR20013 + dexamethasone + palonosetron placebo
- **DRUG:** Palonosetron + dexamethasone + HR20013 placebo

## Key facts

- **NCT ID:** NCT06554184
- **Lead sponsor:** Fujian Shengdi Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-09-03
- **Primary completion:** 2025-07-28
- **Final completion:** 2025-10-03
- **Target enrollment:** 706 (ACTUAL)
- **Last updated:** 2025-11-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06554184

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06554184, "HR20013 for Nausea and Vomiting Associated With Moderate Emetic Risk Anticancer Agents". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06554184. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*